IL13Rα2-Specific CAR T Cells for Solid Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for cancer lack specific targets for solid tumors, as most human cancers do not express predictable and effective antigens, limiting the effectiveness of treatments like adoptive immunotherapy, which struggles to target a wide range of solid tumors effectively.
Innovation Solution
Development of T cells expressing a chimeric antigen receptor (CAR) specifically recognizing the Interleukin 13 Receptor α2 (IL13Rα2), which is selectively expressed on various tumor types, including glioblastoma, to enable targeted killing of IL13Rα2-positive cells while minimizing interaction with normal tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T cells are used for adoptive immunotherapy targeting cancer antigens, then tumor destruction capability is improved, but toxicity to normal tissues expressing the same antigens worsens
Solution Approach 1:
The patent applies local quality by creating T cells with chimeric antigen receptors that are specifically tailored to recognize IL13Rα2. This localized specificity ensures that the immunotherapeutic effect is concentrated on tumor cells expressing this particular antigen variant, while sparing normal tissues that express different antigen profiles or lower levels of IL13Rα2.
Solution Approach 2:
The invention utilizes parameter changes by modifying the antigen recognition parameters of T cells through CAR engineering. By changing the receptor specificity from general IL-13 recognition to specific IL13Rα2 recognition, the patent alters the binding affinity and selectivity parameters, enabling discrimination between tumor and normal cells based on antigen expression patterns.
2Adaptability or versatility
If broad-spectrum cancer antigens are targeted to treat multiple tumor types, then versatility of treatment is improved, but specificity to cancer cells worsens
Solution Approach 1:
The patent applies universality by demonstrating that IL13Rα2 is expressed across multiple solid tumor types including glioblastoma, ovarian cancer, and pancreatic cancer. A single CAR T cell product targeting this antigen can therefore be universally applied to treat various tumor types, providing multi-functional therapeutic capability.
Solution Approach 2:
The invention uses copying by creating a standardized CAR T cell platform that can be replicated and applied across different cancer indications. Once the IL13Rα2-targeting CAR is developed and validated, it can be copied and deployed for treating multiple tumor types expressing this antigen, avoiding the need to develop separate therapies for each cancer type.
3Productivity
If high affinity binding to target antigen is achieved to improve killing efficiency, then tumor cell destruction is improved, but cross-reactivity with normal tissue receptors worsens
Solution Approach 1:
The patent applies local quality by engineering CAR T cells with optimized affinity parameters specifically for IL13Rα2 binding. The chimeric antigen receptor is designed to achieve high local concentration and strong binding at the tumor cell surface where IL13Rα2 is overexpressed, while the specificity of the binding interface prevents cross-reactivity with normal tissue receptors.
Solution Approach 2:
The invention utilizes dynamics by creating a CAR T cell system where binding affinity is optimized for the specific tumor microenvironment. The dynamic interaction between the CAR and IL13Rα2 allows for high-affinity binding when the antigen is present at tumor-relevant expression levels, while physiological regulation prevents excessive binding to normal tissues with lower antigen expression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IL13Rα2-specific CAR T cells demonstrate potent anti-tumor activity, inducing IL2 production and effective tumor regression in vivo, providing a promising approach for treating cancers with limited toxicity to normal tissues.
Implementation Method 1
T cells expressing a chimeric antigen receptor (CAR) that specifically recognizes and binds to the α2 Interleukin 13 Receptor (i.e., IL13Rα2)
Implementation Method 2
47-CARs with a short spacer region, or SSR (i.e., 47-CAR.SSR), exhibit greater capacity to induce IL2-production in an antigen-dependent manner
Implementation Method 3
The IL13Rα2-specific CARs, generally referred to herein as 47-CARs, when expressed in T cells effectively target and kill IL13Rα2-positive target cells
Data Source
AI summary
Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13Rα2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13Rα2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).